| Document Date: 2012-04-17 11:28:17
Open Document File Size: 145,69 KBShare Result on Facebook
City Reference / / Company Savient Pharmaceuticals Inc. / / Event FDA Phase / / IndustryTerm colorless solution / healthcare settings / healthcare providers / mg/mL solution / healthcare setting / / MedicalCondition arrhythmia / Congestive Heart Failure / hypertension / Congestive Heart Failure KRYSTEXXA / chest pain / disease / insulin dependent diabetes mellitus / nasopharyngitis / dyspnea / Carcinogenesis / cardiac failure/left ventricular dysfunction / dyslipidemia / nausea / Gout Flares Gout / ANAPHYLAXIS / diabetes / erythema / G6PD deficiency / delayed-type hypersensitivity / type hypersensitivity / vomiting / gout / chronic kidney disease / urticaria / chronic gout / coronary artery disease / chronic gout refractory / Deficiency / constipation / pruritus / rash / methemoglobinemia / wheezing / / MedicalTreatment intravenous infusion / / Organization Before administration / DOSAGE AND ADMINISTRATION / FDA / / / Position physician / General / / Product acetaminophen / Sodium Chloride / KRYSTEXXA / / Region Mediterranean / / Technology Pharmacokinetics / mPEG / antibodies / microwave / Pharmacodynamics / / URL www.fda.gov/medwatch / /
SocialTag |
Krystexxa (pegloticase) injection label